Active	Status	Sponsor type	Region	Phase	Filter
5 Active 0 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

5 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
McPherson, Amber K
CELLO, NCT04877457: Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.	Terminated	4	3	US	Ocrelizumab, Placebo	Yale University, Genentech, Inc.	Radiologically Isolated Syndrome, Multiple Sclerosis	06/23	06/23
MoveS-it, NCT04602390: Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis	Completed	1	33	US	ANK-700, Placebo	Anokion SA	Multiple Sclerosis (MS), Relapsing Remitting Multiple Sclerosis	04/24	04/24
Moreo, Natalie
CELLO, NCT04877457: Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.	Terminated	4	3	US	Ocrelizumab, Placebo	Yale University, Genentech, Inc.	Radiologically Isolated Syndrome, Multiple Sclerosis	06/23	06/23
NCT06220669: A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis	Recruiting	2	200	Europe, US, RoW	LY3541860, Placebo	Eli Lilly and Company	Multiple Sclerosis	08/27	08/28
NCT04711148: A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis	Active, not recruiting	2	160	Europe, US, RoW	placebo, orelabrutinib	Beijing InnoCare Pharma Tech Co., Ltd.	Relapsing Remitting Multiple Sclerosis	02/26	03/26